scholarly journals Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment

2017 ◽  
Vol 13 (6) ◽  
pp. 3624-3630
Author(s):  
Xu Li ◽  
Qinglong Jin ◽  
Hongqin Xu ◽  
Zetian Zhang ◽  
Hongjie Zhou ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Treatment ◽  
High Liver

scholarly journals High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers

Hepatology ◽  
2015 ◽  
Vol 61 (4) ◽  
pp. 1261-1268 ◽  
Author(s):  
Beomseok Suh ◽  
Sehhoon Park ◽  
Dong Wook Shin ◽  
Jae Moon Yun ◽  
Hyung-Kook Yang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Liver Fibrosis Index ◽  
High Liver

scholarly journals Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index

2020 ◽  
Vol 7 (1) ◽  
pp. e000543
Author(s):  
Ta-Wei Liu ◽  
Chung-Feng Huang ◽  
Ming-Lun Yeh ◽  
Pei-Chien Tsai ◽  
Tyng-Yuan Jang ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Treatment ◽  
University Hospital ◽  
Treatment Naïve ◽  
The Difference ◽  
Fibrosis Marker

Background and aimsChronic hepatitis B patients in Taiwan with no or limited liver injury are not reimbursed for antiviral treatment by the Taiwan National Health Insurance (NHI). Innovative fibrosis marker, age-adjusted Fibrosis-4 Index (FIB4-AA), was implemented to evaluate the tendency of liver fibrosis in these patients.MethodsThe FIB-4 indices of 256 antiviral treatment-naïve chronic hepatitis B patients at Kaohsiung Medical University Hospital from 2003 to 2019 were reviewed. The difference in initial FIB-4 and last FIB4-AA was treated as a categorical variable, representing the tendency of liver fibrosis in each individual aside from ageing. Logistic regression was implemented to evaluate the three parameters most dependent on increment of FIB4-AA: e seroconversion, body mass index (BMI) and initial FIB-4 index.ResultsThe yearly FIB-4 growth rate of an individual without chronic hepatitis was lower than that of the study group (0.0237 vs 0.0273 for males, 0.02 vs 0.0288 for females). Patients undergoing or completing e seroconversion were less prone to increment of FIB4-AA (p=0.036, OR 0.524). Logistic regression revealed that BMI ≥25 kg/m2 significantly less increment of FIB4-AA (p=0.001, OR 0.383, 95% CI 0.212 to 0.690), while patients with initial FIB-4 <1.29 were prone to increasing liver FIB4-AA (p=0.000, OR 3.687, 95% CI 1.999 to 6.797).ConclusionChronic hepatitis B patients not meeting the reimbursement criteria of the Taiwan NHI are prone to increment of liver fibrosis marker. Overweight is associated with less increment of fibrosis marker, while initial FIB-4 <1.29 is associated with increasing fibrosis marker.

scholarly journals Clinical features of chronic B hepatitis in children depending on treatment response

2020 ◽  
Vol 4 (11) ◽  
pp. 682-686
Author(s):  
O.V. Churbakovа ◽  
◽  
V.G. Akimkin ◽  
D.V. Pechkurov ◽  
◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Treatment Response ◽  
Chronic Hepatitis B ◽  
Clinical Features ◽  
Sustained Virologic Response ◽  
Antiviral Treatment ◽  
Virologic Response

Background: chronic hepatitis is a common infection in all age groups. The optimization of therapeutic approaches is an important medical social and national economic issue. Aim: to describe the clinical and laboratory features of chronic hepatitis B (CHB) in children depending on the efficacy of antiviral therapy. Patients and Methods: 31 children aged 3–17 years with НBeAg-negative CHB who were treated in the Children’s Infectious Department of N.A. Semashko Samara City Clinical Hospital No. 2 and then monitored in a children’s hepatological center were enrolled. These children received no prior antiviral treatment. T he efficacy of antivirals and CHB outcomes over a 6-year perio d were evaluated. Results: the changes in clinical and biochemical parameters in children with CHB depending on treatment response were analyzed. All children were prescribed with antiviral therapy according to Diagnosis and Treatment Protocol for Hepatitis B and C (2010). In 14 (45.2%) children who received antiviral therapy, sustained virologic response was achieved after 48 weeks. In these children, no cases of liver fibrosis were reported over a 6-year period. Meanwhile, in the group without sustained virologic response after antiviral therapy (n=17), 1 patient was diagnosed with liver fibrosis stage 1 and 2 patients were diagnosed with Child class A cirrhosis. Conclusion: despite countrywide HBV vaccination, the incidence of CHB is still high thus requiring the development of novel diagnostic and therapeutic strategies. KEYWORDS: chronic hepatitis B, children, differential therapy, viral host response, prognosis. FOR CITATION: Churbakovа O.V., Akimkin V.G., Pechkurov D.V. Clinical features of chronic B hepatitis in children depending on treatment response. Russian Medical Inquiry. 2020;4(11):682–686. DOI: 10.32364/2587-6821-2020-4-11-682-686.

Sign in / Sign up

Export Citation Format

Share Document